Physician profile
Lance Berger
NPI 1689679490
$11,888.46
in general payments reported to CMS, 2019-2025
30 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,752 · 2020: $68.46 · 2021: $413 · 2022: $1,429 · 2023: $1,452 · 2024: $5,864 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,600 · Food and Beverage: $2,743 · Travel and Lodging: $863 · Education: $19.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,600.00 |
| Food and Beverage | $2,743.14 |
| Travel and Lodging | $863.18 |
| Education | $19.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,145.56 | 2019-2025 | |
| Abbott Laboratories | $1,394.40 | 2019-2025 | Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $1,325.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $747.86 | 2019-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $704.55 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $464.34 | 2019-2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $286.85 | 2024-2025 | Amvuttra, Onpattro |
| Daiichi Sankyo INC. | $128.95 | 2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $105.58 | 2019-2021 | |
| Irhythm Technologies, INC. | $99.98 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Biosense Webster, INC. | $70.57 | 2019-2020 | |
| Heartflow, INC. | $47.55 | 2025 | |
| Portola Pharmaceuticals, LLC | $42.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.93 | 2019-2024 | Jardiance |
| Amgen INC. | $30.08 | 2024-2025 | Repatha, Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.65 | 2019-2022 | |
| Esperion Therapeutics, INC. | $27.14 | 2021 | |
| Livanova USA, INC. | $26.21 | 2019 | |
| Scpharmaceuticals INC. | $20.10 | 2025 | |
| Cleerly, INC. | $19.56 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Novo Nordisk INC | $18.98 | 2025 | Wegovy |
| Philips North America LLC | $18.77 | 2025 | Mcot |
| Actelion Pharmaceuticals US, INC. | $16.31 | 2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $15.82 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.59 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $14.80 | 2019 | |
| Bridgebio Pharma, INC. | $13.87 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $13.81 | 2021 | |
| Acarix USA INC. | $13.21 | 2024 | Cadscor System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.